文献速递细菌感染、耐药与抗菌药物医院感染防控

头孢他啶/阿维巴坦治疗血液恶性肿瘤患者疑似或确诊感染的临床影响:一项多中心观察性真实世界研究

Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

在意大利17个血液病房开展回顾性观察研究,纳入198例接受头孢他啶/阿维巴坦治疗疑似或确诊感染的血液恶性肿瘤患者,30天全因死亡率为17.7%,感染复发4例,30天死亡独立关联于感染起病时脓毒性休克和初始抗生素治疗不充分。

要点

  • 198例中66例为不明原因发热,132例为微生物学确诊感染。
  • 肠杆菌目细菌引起98例确诊感染,其中KPC生产者占75%。
  • 30天死亡独立关联于感染起病时脓毒性休克和初始抗生素治疗不充分。

核心结论

  • 本研究为头孢他啶/阿维巴坦治疗血液恶性肿瘤患者感染的有效性提供了进一步证据。

研究设计与样本

  • 回顾性观察性研究,在意大利17个血液病房开展,纳入198例接受头孢他啶/阿维巴坦治疗疑似或确诊感染的血液恶性肿瘤患者。

主要发现

  • 198例中66例为不明原因发热,132例为微生物学确诊感染(MPI)。
  • 肠杆菌目细菌引起98例MPI,其中KPC生产者占75%;碳青霉烯耐药铜绿假单胞菌引起25%的MPI。
  • 总体30天死亡率为17.7%;4例MPI患者发生感染复发。
  • 30天内死亡的患者倾向于有既存脑血管疾病、Charlson合并症指数>4以及感染起病时脓毒性休克,并接受了不充分的初始抗生素治疗。
  • 30天死亡率独立关联于感染起病时脓毒性休克和不恰当的初始抗生素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate clinical impact of ceftazidime/avibactam on treating infections due to MDR Gram-negative bacteria in patients with haematological malignancies (HMs). METHODS: We conducted a retrospective, observational study at 17 Italian haematological wards that included patients with HMs receiving ceftazidime/avibactam for the treatment of suspected or proven infections. The primary endpoint was all-cause mortality 30 days after infection onset. Secondary endpoints included the development of in vitro ceftazidime/avibactam resistance, adverse reactions and infection relapse. RESULTS: Of 198 patients enrolled, 66 had fever of unknown origin and 132 had microbiologically proven infections (MPIs). Enterobacterales were responsible for 98 MPIs, with KPC producers accounting for 75% of these, and carbapenem-resistant Pseudomonas aeruginosa caused 25% of MPIs. The overall 30-day mortality rate was 17.7%. Infection relapse occurred in four patients with MPI. Patients who died within 30 days of infection onset tended to have pre-existing cerebrovascular diseases, a Charlson Comorbidity Index > 4 and septic shock at infection onset and had received inadequate initial antibiotic therapy. Thirty-day mortality was independently associated with septic shock at infection onset and inappropriate initial antibiotic therapy. CONCLUSIONS: Our study provides further evidence about the effectiveness of ceftazidime/avibactam in treating infections in patients with HMs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tumbarello M, Giuliano G, Criscuolo M, et al. Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study. J Antimicrob Chemother. 2025. PMID: 39545817. doi:10.1093/jac/dkae416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。